Patents by Inventor Xavier Lucas Cabré

Xavier Lucas Cabré has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMIDAZO[4,5-B]PYRIDINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS SIK MODULATORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
    Publication number: 20250127780
    Abstract: The invention relates to a compound of formula (I) wherein L, A1, A2, R1, R2, R3, R4 and R5 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: December 18, 2024
    Publication date: April 24, 2025
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guillaume DÉCORET, Katrin GROEBKE ZBINDEN, Wolfgang HAAP, Lukas KREIS, Xavier LUCAS CABRÉ, Jean-Yves WACH, Roger WERMUTH
  • PYRIDINE DERIVATIVES
    Publication number: 20250115607
    Abstract: The invention relates to a compound of formula (I) wherein A1, R1, R2, R3, R4 and R5 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: December 18, 2024
    Publication date: April 10, 2025
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guillaume DÉCORET, Katrin GROEBKE ZBINDEN, Wolfgang HAAP, Lukas KREIS, Xavier LUCAS CABRÉ, Etienne RAUBER
  • Benzimidazole Pyridine Derivatives
    Publication number: 20240383875
    Abstract: The invention relates to a compound of formula (I) wherein A1, A2, A3, R1, R2, R2?, R3, R4 and R5 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: July 18, 2024
    Publication date: November 21, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Mahendra AWALE, Stefan BERCHTOLD, Julie CHARPENTIER, Héloïse Marie Albine COLOMBANO, Guillaume DECORET, Katrin GROEBKE ZBINDEN, Nicole GROSSMANN, Wolfgang HAAP, Philip Anthony HARRIS, Jérôme HERT, Jonah Milton KALLENBACH, Christian KRAMER, Lukas KREIS, Danny KRUMM, Xavier LUCAS CABRE, Nenad MANEVSKI, Philippe PFLIEGER, Amir Mohsen POURMOUSA ABKENAR, Etienne RAUBER, Dazhi TAN, Jean-Yves WACH, Roger WERMUTH
  • TARGETED DEGRADATION OF VAV1
    Publication number: 20240285604
    Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that degrades Proto-oncogene VAV 1 protein (VAV1). The chemical entities are useful, e.g., for treating a subject (e.g., a human subject) having an inflammatory or autoimmune disorder.
    Type: Application
    Filed: April 11, 2024
    Publication date: August 29, 2024
    Inventors: Laura Ann McAllister, Elisa Liardo, Andreas Ritzen, Vladas Oleinikovas, Xavier Lucas Cabré, Bernhard Fasching, Lorenzo Delarue Bizzini, Mathieu Lesieur